Demographics of the study cohort
| Characteristic . | N = 174 . |
|---|---|
| Diagnosis, n (%) | |
| ASM | 27 (16) |
| SM-AHN | 119 (68) |
| MCL | 28 (16) |
| Age | |
| Median (IQR) | 68 (61-73) |
| Range | 31-88 |
| Sex, n (%) | |
| Male | 102 (59) |
| Female | 72 (41) |
| Race, n (%) | |
| White | 150 (86) |
| Black or African American | 1 (1) |
| Asian | 3 (2) |
| Other/unknown | 20 (11) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 2 (1) |
| Not Hispanic or Latino | 156 (90) |
| Unknown | 16 (9) |
| Months between initial diagnosis and clinical trial screening | |
| Median (IQR) | 11 (4-30) |
| Range | 0-638 |
| Unknown | 2 |
| Months between last therapy and clinical trial screening | |
| Median (IQR) | 1.41 (0.82-3.78) |
| Range | 0-242 |
| No. of previous therapies | |
| Median (IQR) | 1 (0-2) |
| Range | 0-6 |
| Previous treatment with midostaurin, n (%) | 81 (47) |
| Serum tryptase, ng/mL | |
| Median (IQR) | 210 (125-432) |
| Range | 12-1600 |
| BM mast cell burden, % | |
| Median (IQR) | 40 (20-70) |
| Range | 1-95 |
| Unknown | 6 |
| No. of WHO organ damage findings | |
| Median (IQR) | 1 (1-2) |
| Range | 0-5 |
| No. of mIWG organ damage findings | |
| Median (IQR) | 1 (0-3) |
| Range | 0-6 |
| Characteristic . | N = 174 . |
|---|---|
| Diagnosis, n (%) | |
| ASM | 27 (16) |
| SM-AHN | 119 (68) |
| MCL | 28 (16) |
| Age | |
| Median (IQR) | 68 (61-73) |
| Range | 31-88 |
| Sex, n (%) | |
| Male | 102 (59) |
| Female | 72 (41) |
| Race, n (%) | |
| White | 150 (86) |
| Black or African American | 1 (1) |
| Asian | 3 (2) |
| Other/unknown | 20 (11) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 2 (1) |
| Not Hispanic or Latino | 156 (90) |
| Unknown | 16 (9) |
| Months between initial diagnosis and clinical trial screening | |
| Median (IQR) | 11 (4-30) |
| Range | 0-638 |
| Unknown | 2 |
| Months between last therapy and clinical trial screening | |
| Median (IQR) | 1.41 (0.82-3.78) |
| Range | 0-242 |
| No. of previous therapies | |
| Median (IQR) | 1 (0-2) |
| Range | 0-6 |
| Previous treatment with midostaurin, n (%) | 81 (47) |
| Serum tryptase, ng/mL | |
| Median (IQR) | 210 (125-432) |
| Range | 12-1600 |
| BM mast cell burden, % | |
| Median (IQR) | 40 (20-70) |
| Range | 1-95 |
| Unknown | 6 |
| No. of WHO organ damage findings | |
| Median (IQR) | 1 (1-2) |
| Range | 0-5 |
| No. of mIWG organ damage findings | |
| Median (IQR) | 1 (0-3) |
| Range | 0-6 |
IQR, interquartile range.